BETV4 belongs to the polcalcin superfamily, characterized by its ability to bind calcium ions and mediate allergic reactions. It is a recombinant protein produced in either insect cells (SF9) or E. coli, with applications in allergy diagnostics and immunological studies .
Property | Value/Description | Source |
---|---|---|
Molecular Weight | ~10.3–10.4 kDa (recombinant) | |
Source Organism | Betula pendula (mature pollen) | |
Recombinant Production | SF9 insect cells or E. coli | |
Tags | 6xHis tag (N-terminal) |
Parameter | SF9 (Prospec Bio) | E. coli (Sino Biological) |
---|---|---|
Purity | >80% | >95% |
Formulation | 20 mM HEPES, 6M urea | Not specified |
Storage | -20°C | -20°C to -80°C |
Applications | Immunodot tests, IgE binding | Research use, allergy diagnostics |
BETV4’s primary role lies in its interaction with the human immune system:
IgE Binding: Acts as a ligand for IgE antibodies, enabling diagnostic assays to identify allergen-specific responses .
Cross-Reactivity: Serves as a marker for plant polysensitization, where IgE antibodies react with homologous proteins across plant species .
Immunodot Testing: Used in serum panels to differentiate between true sensitization and cross-reactivity in allergy diagnostics .
BETV4 is employed in:
Allergy Diagnostics: Validates IgE-specific responses in patient sera.
Polcalcin Studies: Investigates calcium-dependent allergenicity and cross-reactivity mechanisms.
Therapeutic Development: Serves as a model for desensitization strategies in allergy immunotherapy.
Allergenic Activity: Demonstrated IgE binding in immunodot assays with positive sera panels .
Stability: Retains functionality in formulations containing urea, enabling long-term storage .
Purity Impact: Higher purity (>95%) in E. coli-produced BETV4 may enhance assay reliability compared to SF9-derived preparations .
Polcalcin Bet v 4, Calcium-binding pollen allergen Bet v 4, Bet v 4, BETV4.
BETV4 is a calcium-binding protein of 2-EF-hand type primarily expressed in mature birch (Betula verrucosa) pollen. It functions as an allergen, causing allergic reactions in humans, and exists in pollen of various plant species. Due to its cross-reactivity, BETV4 serves as a marker allergen for plant polysensitization .
It's important to note that literature contains some inconsistency regarding BETV4's identity. While some sources describe it as a pollen allergen , others characterize it as a member of the BET (bromodomain and extra-terminal) family of proteins involved in gene regulation and transcriptional control . This FAQ focuses primarily on BETV4 as the pollen allergen.
Recombinant BETV4 for research is typically produced in Sf9 insect cells as a glycosylated polypeptide chain with a calculated molecular mass of 10,473 Dalton. The protein is expressed with a 6xHis tag at the N-terminus to facilitate purification through proprietary chromatographic techniques. The final product is supplied as a sterile filtered clear solution in 20mM HEPES buffer (pH 7.9) containing 6M Urea .
For optimal experimental results, researchers should follow these stability guidelines:
Storage Period | Recommended Temperature | Notes |
---|---|---|
Short-term (2-4 weeks) | 4°C | If entire vial will be used within this period |
Long-term | -20°C | For extended storage periods |
Multiple use | Varies | Avoid multiple freeze-thaw cycles |
Proper storage conditions are critical to maintaining the protein's immunological functions, including its ability to bind IgE-type human antibodies .
Several analytical techniques have been validated for BETV4 research:
Technique | Application | Recommended Parameters | Research Considerations |
---|---|---|---|
Western Blotting | Protein detection | Antibody dilution: 1:500-1:5000 | Useful for analyzing expression in complex samples |
ELISA | Quantitative analysis | Antibody dilution: 1:2000-1:10000 | Provides sensitive quantification of BETV4 levels |
Immunodot Test | Qualitative detection | Using positive/negative sera panels | Efficient for screening multiple samples |
When using antibody-based detection, the BETV4 polyclonal antibody (PACO50214) has been validated for Western blotting and ELISA applications. This antibody is raised against recombinant Betula pendula Polcalcin Bet v 4 protein (amino acids 1-85) and purified using Protein G to >95% purity .
While specific experimental designs for BETV4 aren't explicitly described in the literature, researchers can apply Bayesian optimal experimental design principles to maximize information gained from BETV4 studies. These approaches include:
Implementing search algorithms from artificial intelligence that efficiently explore possible design parameters
Utilizing sampling procedures to evaluate design parameter combinations more efficiently
Collecting data across different experimental designs to compare their ability to discriminate among competing models of BETV4 function
These computational improvements make experimental procedures more tractable and can significantly reduce the amount of data required to distinguish between behavioral models of allergic responses to BETV4.
Transcriptomic analysis of BETV4 expression requires careful consideration of several methodological challenges:
Sequence processing and assembly can be performed using tools like 454 Newbler with default parameters (40 bp overlap and 90% identity)
Translation frame assessment should be conducted through BLASTx searches against relevant databases
Proper annotation requires tools such as InterProScan and Gene Ontology terms
To identify differential gene expression between samples, contigs should be clustered using applications like CD-Hit 454 (90% similarity) to eliminate redundant sequences
Statistical analysis must employ appropriate normalization methods and linear regression models based on Gaussian distribution
Researchers should ensure they include only contigs with a minimum threshold of mapped reads (e.g., eight or more) and apply appropriate false discovery rate controls.
BETV4's calcium-binding structure makes it an important marker for cross-reactivity studies. As a polcalcin present in various plant pollens, it can help identify patients with polysensitization patterns. When designing cross-reactivity studies, researchers should:
Incorporate BETV4 in multiplex testing panels alongside other calcium-binding pollen allergens
Apply cluster analysis to identify patterns of sensitization across patient populations
Consider BETV4 as a potential marker when investigating patients with multiple plant allergies
Understanding these cross-reactivity patterns has significant implications for both diagnosis and immunotherapy approaches.
Cluster analysis of molecular components in patients with atopic dermatitis has shown that sensitization to molecular allergens is a significant factor. While specific percentages for BETV4 sensitization aren't provided in the available research, studies indicate that sensitization to molecular fungal allergens was recorded in 58% of atopic dermatitis patients .
Researchers investigating BETV4's role in atopic dermatitis should consider:
Using ISAC Multiplex testing to simultaneously assess sensitization to multiple allergens including BETV4
Applying cluster analysis to identify patterns of sensitization
Correlating BETV4 sensitization with clinical manifestations of atopic dermatitis
Validation of immunological assays for BETV4 should include:
Confirmation of binding to IgE-type human antibodies
Verification through immunodot tests with both positive and negative sera panels
Assessment of specificity through cross-reactivity testing with related allergens
Evaluation of sensitivity using standardized allergen preparations
Researchers should document purification methods, storage conditions, and quality control metrics when reporting results from BETV4 immunological assays.
BETV4 is a calcium-binding protein featuring a 2-EF-hand structural motif. The EF-hand domains consist of helix-loop-helix structures that bind calcium ions. These structural features are critical to understanding BETV4's:
Ability to bind calcium ions, which may affect protein conformation
Interaction with IgE antibodies from allergic patients
Cross-reactivity with similar calcium-binding proteins from other plant species
Structural studies of BETV4 are essential for developing targeted therapeutic approaches for birch pollen allergies.
To conduct comparative studies of BETV4 across plant species, researchers should consider:
Sequence alignment analysis to identify conserved domains and variable regions
Recombinant expression of BETV4 homologs from different species for functional comparison
Structural analysis of calcium-binding domains across species
Immunological cross-reactivity testing using patient sera
Transcriptomic profiling to compare expression patterns in different plant species and tissues
These comparative approaches can help identify conserved allergenicity determinants and species-specific variations that might affect diagnosis and treatment.
When designing antibodies for BETV4 research, several factors are critical:
Consideration | Details | Research Implications |
---|---|---|
Immunogen Selection | Recombinant Betula pendula Polcalcin Bet v 4 protein (1-85AA) | Ensures specificity to the target protein |
Host Species | Rabbit (for polyclonal antibodies) | Affects downstream application compatibility |
Purification Method | Protein G purification (>95% purity) | Influences specificity and background signal |
Storage Buffer | 0.03% Proclin 300, 50% Glycerol, 0.01M PBS, pH 7.4 | Critical for antibody stability and performance |
Validated Applications | ELISA (1:2000-1:10000), WB (1:500-1:5000) | Determines research application suitability |
Researchers should validate antibody performance in their specific experimental systems before proceeding with large-scale studies .
Applying optimal experimental design principles to BETV4 research offers several advantages:
More efficient exploration of experimental design parameters through AI-based search algorithms
Reduced data requirements for model discrimination through Bayesian optimization approaches
Improved ability to dynamically optimize online experiments
Enhanced capability to test competing hypotheses about BETV4's role in allergic responses
Advanced transcriptomic approaches that could enhance BETV4 expression research include:
Deep sequencing with proper removal of ribosomal, mitochondrial, and chloroplast reads
Assembly of sequences using tools like 454 Newbler 2.6 with appropriate overlap and identity parameters
Translation frame assessment using BLASTx searches against Swiss-Prot
Annotation with InterProScan and Gene Ontology terms
Differential expression analysis using normalized read counts and appropriate statistical models
These methodologies can provide deeper insights into the regulation of BETV4 expression across different plant tissues and environmental conditions.
Understanding BETV4's molecular characteristics and cross-reactivity patterns has important implications for allergen immunotherapy:
Its role as a marker allergen for plant polysensitization could help identify patients who might benefit from specific immunotherapy approaches
Structural studies could inform the design of hypoallergenic variants for safer immunotherapy
Cross-reactivity patterns might explain clinical responses to immunotherapy targeting related allergens
Comparative studies across plant species could help develop broader-spectrum immunotherapy approaches
Research in this area requires careful integration of molecular, immunological, and clinical data to translate findings into improved patient care.
Bet v 4 is considered a minor allergen because it is recognized by the immune system of a smaller percentage of individuals allergic to birch pollen. Studies have shown that about 20% of patients allergic to birch pollen have specific IgE antibodies against Bet v 4 . Despite being a minor allergen, Bet v 4 plays a significant role in the diagnosis and management of birch pollen allergies.
Recombinant Bet v 4 is produced using genetic engineering techniques. The gene encoding Bet v 4 is cloned and expressed in a suitable host organism, such as Escherichia coli . The recombinant protein is then purified, often using immobilized metal affinity chromatography, to achieve high purity levels suitable for research and diagnostic applications .
Recombinant Bet v 4 is primarily used in allergen-specific IgE antibody testing. It helps in the diagnosis of birch pollen allergies and can be used to identify individuals who are polysensitized to multiple pollen allergens . The recombinant form of Bet v 4 is also valuable in research studies aimed at understanding the molecular mechanisms of allergic reactions and developing new therapeutic approaches.
The prevalence of sensitization to Bet v 4 varies geographically. For instance, studies have reported that 5% of individuals in Finland, 8% in Sweden, 11% in Austria, 6% in France, 27% in Italy, and 7% in Switzerland have specific IgE antibodies against Bet v 4 . In Japan, only 2.5% of birch-allergic individuals were found to have IgE antibodies against Bet v 4 .
Polcalcin Bet v 4 is known to be highly cross-reactive with other polcalcins found in different pollen species. This cross-reactivity can lead to polysensitization, where individuals are allergic to multiple pollen types. For example, polcalcins from timothy grass (Phl p 7) and alder (Aln g 4) can also trigger allergic reactions in individuals sensitized to Bet v 4 .